Gynecological cancers

Recommended treatments for these cancers commonly cause CINV^16,17

Highly emetogenic chemotherapy (HEC) regimens including agents such as
- Cisplatin
- Carboplatin
Chemotherapy in combination with abdominal/pelvic radiation, potentiating CINV effects

Specific issues underscore the need for a simple and effective option to prevent CINV

Gender	Females are more susceptible to CINV compared to males¹³ A history of morning sickness during pregnancy can increase CINV risk up to 2.5 times¹⁴
Polypharmacy	Patients taking a lot of pills may be less compliant with medications at home¹⁸ In a survey of 100 hospitalized cancer patients, each received an average of 8 non-chemotherapy-related drugs¹⁹
Fatigue	Emotionally and physically exhausted patients may be less likely to be compliant with medications at home²⁰ Hauser et al report that fatigue is universal in cancer patients²⁰

SANCUSO is the right choice

Successfully studied in ovarian and cervical cancers in a phase III trial²
Helps to avoid the increased risk of CINV due to patient demographic characteristics
and platinum-based regimens¹
Provides continuous coverage with one application, so adherence to treatment is not an issue¹

IMPORTANT SAFETY INFORMATION
SANCUSO^® (Granisetron Transdermal System) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.¹ SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the patch.¹ Granisetron may mask a progressive ileus and/or gastric distention caused by the underlying condition.¹ Mild application site reactions have occurred; remove the patch if severe reaction or a generalized skin reaction occurs.¹ Patients should avoid direct exposure of application site to natural or artificial sunlight by covering with clothing while wearing the patch and for 10 days after removing it.¹ The most common adverse reaction in patients receiving SANCUSO is constipation (5.4%).¹ SANCUSO contains granisetron.¹ Healthcare professionals should avoid prescribing any additional products that contain granisetron. No clinically relevant drug interactions have been reported in clinical studies with SANCUSO.¹

Gynecological cancers

Recommended treatments for these cancers commonly cause CINV16,17

Specific issues underscore the need for a simple and effective option to prevent CINV

Gender

Polypharmacy

Fatigue

SANCUSO is the right choice

Recommended treatments for these cancers commonly cause CINV^16,17